Product image of Mupina (Mupirocin) supplied by GNH India

Mupina

Active Ingredient:
Mupirocin
Origin:
EU

Mupina (Mupirocin)

Mupirocin, the active ingredient in Mupina, is an antibiotic (monoxycarbolic acid) presented as a topical ointment for nasal use. It is employed to eradicate Staphylococcus aureus, including methicillin‑resistant strains, from the nasal passages of carriers and patients at risk of infection, supporting infection control measures in clinical settings.

GNH India supplies Mupina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union quality standards and is manufactured under GMP conditions.

Manufacturer / TM Owner

Infectopharm Arzneimittel Und Consilium Gmbh, De, Heppenheim

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mupina (mupirocin) is used for nasal decolonisation of Staphylococcus aureus, targeting carriers to reduce infection risk.

  • Nasal decolonisation of Staphylococcus aureus (including MRSA): reduces bacterial carriage in the anterior nares.
  • Pre‑operative nasal decolonisation: lowers the likelihood of postoperative Staphylococcal wound infections.
  • Carrier eradication in healthcare workers: helps eliminate nasal colonisation to prevent transmission in clinical environments.

How It Works

  • Mupirocin inhibits bacterial isoleucyl‑tRNA synthetase, an enzyme essential for protein synthesis. By binding to the active site of the synthetase, it prevents the attachment of isoleucine to its cognate tRNA, halting elongation of the peptide chain. This selective blockade stops bacterial growth and leads to bacteriostatic activity at low concentrations and bactericidal effects at higher concentrations against susceptible Gram‑positive organisms.

Side Effects

Mupina may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Nasal irritation: mild burning or stinging sensation.
  • Pruritus: itching of the nasal mucosa.
  • Rhinorrhea: watery nasal discharge.
  • Headache: mild tension‑type headache.

Serious or Rare Side Effects

  • Allergic contact dermatitis: redness, swelling, or vesicles at the application site.
  • Anaphylaxis: rare systemic hypersensitivity with respiratory distress or hypotension.
  • Superinfection: overgrowth of non‑susceptible organisms leading to secondary infection.

Precautions & Warnings

When using Mupina, consider the following precautions to ensure safe and effective treatment.

  • Indication verification: confirm nasal colonisation with Staphylococcus aureus before treatment.
  • Duration of therapy: limit use to the prescribed period to avoid resistance development.
  • Concomitant antibiotics: avoid simultaneous use of other topical antibiotics in the same area.
  • Pregnancy and lactation: assess risk‑benefit ratio as safety data are limited.
  • Pediatric use: use only under medical supervision in children.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Mupina can interact with other medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Systemic antibiotics with similar spectrum: may increase risk of resistance.
  • Immunosuppressants: heightened risk of infection when bacterial load is not controlled.

Moderate Interactions (Monitor Closely)

  • Antifungal agents applied to the same site: potential for local irritation.
  • Nasal decongestants: may alter mucosal absorption of mupirocin.
  • Topical corticosteroids: could mask signs of local infection.

Frequently Asked Questions

Mupina contains mupirocin and is applied intranasally to eradicate Staphylococcus aureus, including methicillin‑resistant strains, from the nasal passages. It is used for carrier decolonisation, pre‑operative preparation, and infection control in healthcare settings.

Mupirocin blocks bacterial isoleucyl‑tRNA synthetase, an enzyme required for attaching isoleucine to its tRNA. This interruption halts protein synthesis, preventing bacterial growth and leading to bacteriostatic or bactericidal effects against susceptible Gram‑positive organisms.

The prescribed dose of Mupina is determined by the treating clinician based on the patient’s condition, age, and local guidelines. The healthcare professional will specify the amount to apply and the duration of therapy.

Safety data for mupirocin in pregnancy and lactation are limited. Prescribers should weigh potential benefits against possible risks and consider alternative treatments if appropriate. Consultation with a obstetrician or lactation specialist is advised.

To order Mupina, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mupina (mupirocin) is a topical antibiotic with a specific mechanism targeting bacterial protein synthesis, offering high potency against Staphylococcus aureus. Alternatives such as povidone‑iodine or fusidic acid have different spectra and resistance profiles; mupirocin is generally preferred for MRSA carriers due to its proven efficacy.

Store Mupina at room temperature, below 25 °C, in its original packaging. Protect the ointment from moisture, direct sunlight and extreme temperatures. Keep the container tightly closed when not in use to maintain product stability.

Mupina is applied intranasally as a thin layer of ointment to each nostril, usually using a clean fingertip or applicator. The prescriber will indicate the exact amount and frequency, typically twice daily for a defined treatment period.

Serious risks include allergic reactions such as contact dermatitis, systemic anaphylaxis, and secondary bacterial or fungal superinfection due to disruption of normal flora. Patients should seek immediate medical attention if they experience severe rash, swelling, breathing difficulty, or signs of infection.

Mupina should be avoided in individuals with a known hypersensitivity to mupirocin or any component of the formulation. It is also contraindicated in patients with active nasal infections caused by organisms resistant to mupirocin, unless directed by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mupirocin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT